Readystate Asset Management LP Makes New $11.40 Million Investment in Catalent, Inc. (NYSE:CTLT)

Readystate Asset Management LP acquired a new stake in Catalent, Inc. (NYSE:CTLT) in the 3rd quarter, Holdings Channel reports. The fund acquired 188,154 shares of the company’s stock, valued at approximately $11,396,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brooklyn Investment Group purchased a new stake in shares of Catalent in the 3rd quarter valued at approximately $31,000. Sentry Investment Management LLC bought a new position in shares of Catalent during the 3rd quarter worth about $53,000. Longfellow Investment Management Co. LLC boosted its position in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares in the last quarter. GAMMA Investing LLC boosted its position in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. boosted its position in Catalent by 57.5% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock valued at $72,000 after buying an additional 431 shares in the last quarter.

Catalent Trading Up 0.2 %

CTLT opened at $61.80 on Thursday. The company’s 50 day moving average is $60.00 and its 200-day moving average is $58.62. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $62.08. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The company has a market cap of $11.22 billion, a P/E ratio of -27.35, a PEG ratio of 2.44 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the business posted ($0.10) earnings per share. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. Equities research analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Insider Activity

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CTLT shares. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Monday. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Eight analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.